公开(公告)号：US20110059052A1

公开(公告)日：2011-03-10

申请号：US12668592

申请日：2008-12-01

申请人： Jeong Chan Ra ,  Hang Young Lee ,  Jung Youn Jo ,  Yun Jung Kim

发明人： Jeong Chan Ra ,  Hang Young Lee ,  Jung Youn Jo ,  Yun Jung Kim

IPC分类号： A61K35/12 ,  A61P13/10

CPC分类号： A61K35/28 ,  A61K9/0019 ,  A61K35/12 ,  A61K35/50 ,  C12N5/0605 ,  C12N5/0667

摘要： The present invention relates to a cellular therapeutic agent for treating urinary incontinence, and more particularly to a cellular therapeutic agent for treating urinary incontinence, which contains stem cells derived from the decidua of the placenta or menstrual fluid or stem cells derived from adipose. The decidua-derived stem cells or adipose-derived stem cells show the effects of increasing leak point pressure and urethral sphincter contractility, and thus are useful as an agent for treating urinary incontinence.

摘要翻译： 本发明涉及用于治疗尿失禁的细胞治疗剂，更具体地涉及用于治疗尿失禁的细胞治疗剂，其含有衍生自胎盘或月经液的蜕膜或源自脂肪的干细胞的干细胞。 来自蜕膜的干细胞或脂肪来源的干细胞显示增加泄漏点压力和尿道括约肌收缩力的作用，因此可用作治疗尿失禁的药剂。

公开(公告)号：US09982234B2

公开(公告)日：2018-05-29

申请号：US14889434

申请日：2014-02-06

申请人： R BIO CO., LTD. ,  Jeong-Chan Ra

发明人： Jeong-Chan Ra ,  Sung Keun Kang ,  Jung Youn Jo

IPC分类号： C12N5/0775

CPC分类号： C12N5/0667 ,  C12N2500/14 ,  C12N2500/25 ,  C12N2500/30 ,  C12N2500/32 ,  C12N2500/38 ,  C12N2500/76 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/33 ,  C12N2501/39 ,  C12N2501/40 ,  C12N2501/998 ,  C12N2501/999

摘要： The present invention relates to a medium composition for enhancing the self-renewal ability of stem cells, which contains apelin, and a method of culturing stem cells using the medium composition. According to the present invention, stem cells can be effectively cultured to proliferate without changing the characteristics of the cells, and the telomerase activity of stem cells can be increased. Thus, the efficacy of cell therapy based on stem cells can be significantly improved.

公开(公告)号：US20150118748A1

公开(公告)日：2015-04-30

申请号：US14405320

申请日：2013-05-23

申请人： Jeong Chan RA ,  K-STEMCELL CO., LTD.

发明人： Jeong Chan Ra ,  Sung Keun Kang ,  Jung Youn Jo

IPC分类号： C12N5/0775

CPC分类号： C12N5/0667 ,  C12N2500/05 ,  C12N2500/32 ,  C12N2500/33 ,  C12N2500/38 ,  C12N2500/90 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/33 ,  C12N2501/39 ,  C12N2501/999 ,  C12N2511/00

摘要： The present invention relates to a method for preparing stem cells in high concentration. The present invention makes it possible to grow stem cells in an amount sufficient to be clinically usable in a short time, and makes it possible to relatively efficiently enhance the ability of administered stem cells to efficaciously reach target tissue and exhibit an action in a stable fashion and can therefore dramatically increase the efficacy of cell therapy using stem cells.

摘要翻译： 本发明涉及高浓度干细胞的制备方法。 本发明使得可以在短时间内使足量临床使用的量培养干细胞，并且可以相对有效地增强施用的干细胞有效地达到目标组织的能力并以稳定的方式表现出作用 因此可以显着增加使用干细胞的细胞疗法的功效。

公开(公告)号：US20160081917A1

公开(公告)日：2016-03-24

申请号：US14890585

申请日：2014-02-06

申请人： Jeong-Chan RA ,  K-STEMCELL CO., LTD

发明人： Jeong-Chan Ra ,  Sung Keun Kang ,  Jung Youn Jo

IPC分类号： A61K9/00 ,  C12N5/0775 ,  A61K35/28

CPC分类号： A61K9/0019 ,  A61K35/28 ,  A61K47/46 ,  C12N5/0667 ,  C12N2500/38 ,  C12N2500/44 ,  C12N2501/06 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/33 ,  C12N2501/39 ,  C12N2501/91 ,  C12N2501/999 ,  C12N2509/00

摘要： The present invention relates to a stem cell composition for intravenous administration, which contains stem cells at a concentration of 1×107 to 5×108 cells/ml, in which the stem cells have a diameter of 10-20 μm and are present as single cells. The stem cell composition according to the present invention is suitable for intravenous administration, and enables the stem cells to securely reach a target tissue after intravascular administration so as to exhibit their activity in the target tissue. Thus, it can significantly increase the therapeutic effects of the stem cells.

摘要翻译： 本发明涉及用于静脉内给药的干细胞组合物，其含有浓度为1×10 7至5×10 8个细胞/ ml的干细胞，其中干细胞具有10-20μm的直径并以单一形式存在 细胞。 根据本发明的干细胞组合物适用于静脉内施用，并且使得干细胞能够在血管内给药之后牢固地到达靶组织，以便在靶组织中表现出其活性。 因此，它可以显着增加干细胞的治疗效果。